Skip to content

To Evaluate Eye Installation-Tear Free

Evaluation of the Stinging Potential of Products in Human Eyes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02802917
Enrollment
83
Registered
2016-06-16
Start date
2015-05-15
Completion date
2015-05-24
Last updated
2018-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sunscreening Agents

Keywords

Eye stinging potential

Brief summary

The primary objective of this study was to compare the human eye stinging potential of experimental formulas of sun care products \[Sun Protection Factor (SPF) 50 Y49 091, SPF 50 X15 158, SPF 50 X15 160 and SPF 50 X57 162 compared to an industry standard shampoo mixture.

Interventions

DRUGSPF 50 Y49 091 (BAY 987516)

5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

DRUGSPF 50 X15 158 (BAY 987516)

5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

DRUGSPF 50 X15 160 (BAY 987516)

5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

DRUGSPF 50 X57 162 (BAY 987516)

5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

OTHERJ & J baby shampoo, X46 046 (control)

5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.

Sponsors

Bayer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy males or females, 18 to 60 years with no medical conditions of the eyes as determined by the subject's medical history and confirmed by an ophthalmologist * Subjects not under any doctor's care for ocular or peri orbital diseases * The subject will refrain from using contact lenses, any topical facial products, any eye drops, false eyelashes, make up, over the counter products, or cosmetics on their eyes, eyelids, eyelashes, or the periorbital areas of the face during the study.

Design outcomes

Primary

MeasureTime frameDescription
Subjective discomfortup to 10 daysScore 0: No discomfort felt Score 1: Faint, barely perceptible discomfort Score 2: Mild, low intensity discomfort that does not prevent the subject from opening lids Score 3: Moderately intense discomfort that interferes with but does not prevent lid opening Score 4: Severe, very intense discomfort that makes voluntary lid opening difficult, requires force to pull lids apart, and results in the subject requesting washout of test article
Objective lacrimationup to 10 daysScore 0: No tearing or lid wetness above normal Score 1: Noticeable increase in moistness of lid edges - no frank tearing Score 2: Frank tearing - meager flow Score 3: Frank tearing - moderate flow Score 4: Frank tearing - copious flow
Objective conjunctival inflammationup to 10 daysScore 0: Inflammatory changes absent Score 1: Capillaries slightly more prominent than they were at time of baseline examination Score 2: Capillaries very prominent plus some diffuse conjunctival reddening Score 3: Vessels very prominent plus diffuse and confluent intense redness Score 4: Beefy redness and everted lids
Objective cornea and iris inflammationup to 10 daysScore 0: No effect detected with use of slit lamp Score 1: Barely perceptible clouding or pitting of cornea or thickening of iris detected via slit lamp Score 2: Faint clouding or pitting of cornea and/or thickening of the iris Score 3: Moderate clouding or pitting of cornea and/or thickening of the iris Score 4: Intense clouding or pitting of cornea and/or thickening of the iris

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026